The VICC.ORG Directory of Cancers: Treatments, Services & Resources
Skin Cancers and Melanoma
The melanoma program comprises of a diverse group of clinical and laboratory scientists with one common goal: Advancement of the treatment of melanoma.
Skin Cancer
Clinical Trials for Skin Cancers and Melanoma
12 Open Trials
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | VICCMEL1130 02/08/2012 | An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEXGM-CSF or GM-CSF for Eligible Melanoma Patients Participating in Study 005/05 |
| Therapeutic | VICCMEL1120 01/18/2012 | Randomized Phase II trial of MAP Kinase inhibition with AZD6244 hydrogen sulfate in Combination with MK-2206 (Akt inhibitor) in patients with BRAF V600E mutant advanced melanoma whose disease has progressed on prior therapy with a selective BRAF inhibitor (PLX4032/RG7204 or GSK2118436) |
| Therapeutic | VICCMEL1036 10/24/2011 | A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients with Unresectable Stage III or Stage IV Melanoma Disease |
| Therapeutic | ECOGMELE1609 09/08/2011 | A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma |
| Therapeutic | VICCPHI1075 06/01/2011 | VICCPHI1075-A Phase Ib, Open Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Vemurafenib in Combination with GDC-0973 when Administered in BRAFV600E Mutation-Positive Patients Previously Treated (but Without Prior Exposure to BRAF or MEK Inhibitor Therapy) or Previously Untreated for Locally-Advanced / Unresectable or Metastatic Melanoma OR Those who have Progressed after Treatment with Vemurafenib. |
| Therapeutic | VICCMEL1053 04/12/2011 | Randomized Phase II Trial of Temozolomide versus Hyd-Sulfate AZD6244 in Patients with Metastatic Uveal Melanoma |
| Therapeutic | VICCMEL1021 03/25/2011 | The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-Center, Single-Arm Study to Assess the Efficacy of Tasigna? in the Treatment of Patients with Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation |
| Therapeutic | VICCMEL1083 01/05/2011 | An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma |
| Therapeutic | VICCMEL0759 08/01/2008 | A Phase II Study of SU011248 in patients with metastatic mucosal or acral/lentiginous melanoma |
| Correlative | VICCMEL1081 09/28/2011 | The High-Dose Aldesleukin (IL-2) "Select" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High Dose IL-2 Treatment in Patients with Advanced Melanoma |
| Correlative | VICCMEL0287 05/06/2003 | Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository |
| Screen, Detect, Diagnose | VICCMEL09109 06/03/2010 | Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
